Benchmark King Pharmaceuticals' Performance against Key Rivals

LYON, France--(Business Wire)--Reportlinker.com announces that a new market research reportrelated to the Pharmaceutical industry is available in its catalogue. King Pharmaceuticals: PharmaVitae Profile To order that report: www.reportlinker.com/p064473/King-Pharmaceuticals-PharmaVitae-Profile.html

(Due to its length, this URL may need to be copied/pasted intoyour Internet browser's address field. Remove the extra space if oneexists.) For more information, contact Nicolas by emailnbo@reportlinker.com , or by phone +33 4 37 65 17 03. This analysis examines the historical and forecast performance forKing in the ethical pharmaceutical sector. The profile encompassesglobal company strategy, portfolio and pipeline analysis andassessment of financial performance, with 1-6 year sales forecasts forkey drugs. An interactive forecasting and analysis tool providescontinually updated quantitative and qualitative information. Scope Benchmark King Pharmaceuticals' performance against key rivals inthe ethical pharmaceutical sectorSee how King's future depends on thesuccess of its launch portfolio following the patent expiry of severalof the company's key products CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 3 Therapeutic strategy 5 Launch and expiry outlook 7 Externalization, geographic and molecule type strategies 10 Externalization strategy 11 Geographic strategy 12 Molecule type strategy 12 SWOT analysis 13 Strengths 13 Weaknesses 14 Opportunities 14 Threats 15 CHAPTER 2 CORPORATE HISTORY 20 Key findings 20 Background 21 Key corporate developments 21 M&A history 22 Medco Research and Jones Pharma mergers 22 Acquisition of Meridian Medical Technologies and Elan's primarycare business 22 Mylan Laboratories terminates acquisition agreement 22 Current corporate structure 23 Pharmaceuticals 23 Meridian Medical Technology 23 Current management team 24 CHAPTER 3 HISTORICAL PERFORMANCE 25 Key findings 25 Introduction 26 Revenue and growth rate analysis, 2001-06 26 Revenue and growth rate vs. peer set 27 Product analysis, 2001-06 29 Growth drivers 29 Skelaxin 29 Altace 30 Thrombin-JMI 30 Sonata 30 Growth resistors 31 Rest of portfolio 31 Operating revenue and cost analysis, 2001-06 32 Operating revenue/cost analysis 34 CHAPTER 4 FORECAST PERFORMANCE 36 Key findings 36 Introduction 37 Revenue and growth rate, 2006-12 37 Product analysis, 2006-12 39 Growth drivers 44 Altace HCTZ 44 Remoxy 44 Avinza 44 Growth resistors 45 Altace 45 Skelaxin 45 Thrombin-JMI 45 Sonata 45 Therapy area analysis, 2006-12 47 Therapy area growth drivers 49 Central nervous system 49 Therapy area growth resistors 50 Cardiovascular & hematology 50 Therapy area focus 50 Launches and expiries analysis, 2006-12 53 Launch portfolio 53 Avinza (morphine sulfate) 54 Altace HCTZ (ramipril + hydrochlorothiazide) 54 Remoxy (oxycodone) 55 Core portfolio 56 Expiry portfolio 58 Thrombin-JMI 58 Altace 58 Skelaxin 59 Sonata 59 Launch/core/expiry configuration 60 Externalization analysis, 2006-12 63 Geographic analysis, 2006-12 68 Molecule type analysis, 2006-12 72 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 77 Key findings 77 Overview 78 Central nervous system 79 Avinza 79 Overview 79 Sales forecast 80 Newsflow 80 Current market assessment 81 Future market assessment 81 Remoxy 83 Overview 83 Sales forecast 84 Newsflow 84 Future market assessment 85 Competitive landscape 86 Opioid analgesics market dominated by key brands and genericcompetitors 86 The opioid class: potential for abuse 86 Skelaxin 87 Overview 87 Sales forecast 88 Newsflow 88 Current market assessment 89 Future market assessment 89 Cardiovascular & hematology 90 Altace 90 Overview 90 Sales forecast 91 Newsflow 91 Altace HCTZ 94 Overview 94 Sales forecast 95 Newsflow 95 R&D pipeline 97 CHAPTER 6 APPENDIX 98 IMS vs. company-reported data reconciliation 98 References 100 Abbreviations 101 List of Tables Table 1: King's Corporate Executive Committee 24 Table 2: Peer set overview 27 Table 3: Operating revenue/cost analysis ($m), 2001-06 32 Table 4: Operating cost ratio analysis (% of total revenues),2001-06 34 Table 5: Product portfolio overview, sales ($m), 2006-12 39 Table 6: Therapy area overview, sales ($m), 2006-12 47 Table 7: Launch portfolio overview, sales ($m), 2006-12 53 Table 8: Core portfolio overview, sales ($m), 2006-12 56 Table 9: Expiry portfolio overview, sales ($m), 2006-12 58 Table 10: Externally developed portfolio ($m), 2006-12 63 Table 11: Molecule type overview, sales ($m), 2006-12 72 Table 12: Key products overview 78 Table 13: Avinza: overview 79 Table 14: Avinza: sales forecast ($m), 2006-12 80 Table 15: Avinza: newsflow 80 Table 16: Remoxy: overview 83 Table 17: Remoxy: sales forecast ($m), 2006-12 84 Table 18: Remoxy: newsflow 84 Table 19: Skelaxin: overview 87 Table 20: Skelaxin: sales forecast ($m), 2006-12 88 Table 21: Skelaxin: newsflow 88 Table 22: Altace: overview 90 Table 23: Altace: sales forecast ($m), 2006-12 91 Table 24: Altace: newsflow 91 Table 25: Altace HCTZ: overview 94 Table 26: Altace HCTZ: sales forecast ($m), 2006-12 95 Table 27: Altace HCTZ: newsflow 95 Table 28: King Pharmaceuticals pipeline (Phase I-registration) 97 List of Figures Figure 1: Historical and forecast ethical sales performance (%CAGR), King Pharmaceuticals and Mid Pharma peer set 3 Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006 5 Figure 3: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), King Pharmaceuticals 7 Figure 4: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), peer set 8 Figure 5: Key strategic products, sales ($m), 2006-12 9 Figure 6: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2006 10 Figure 7: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2012 11 Figure 8: SWOT analysis of King Pharmaceuticals 13 Figure 9: Current corporate structure 23 Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06 26 Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set,2001-06 28 Figure 12: Growth drivers/resistor products of historical revenueperformance ($m), 2001-06 29 Figure 13: Operating revenue/cost analysis ($m), 2001-06 33 Figure 14: Operating cost ratio analysis (% of total revenues),2001-06 35 Figure 15: Ethical revenue ($m) and growth rate (%), 2006-12 38 Figure 16: Top five products by sales ($m), 2006 40 Figure 17: Top five products by sales ($m), 2012 41 Figure 18: Growth drivers and resistors by product, 2006-12 43 Figure 19: Key strategic products, sales ($m), 2006-12 46 Figure 20: Ethical sales by therapy area ($m), 2006-12 48 Figure 21: Growth drivers and resistors by therapy area ($m),2006-12 49 Figure 22: Ethical sales by therapy area (%), 2006-12 50 Figure 23: Therapy area focus compared with peer set (% totalethical sales), 2006 51 Figure 24: Therapy area focus compared with peer set (% totalethical sales), 2012 52 Figure 25: Launch schedule, sales ($m), 2006-12 55 Figure 26: Core products sales growth ($m), 2006-12 57 Figure 27: Expiry schedule, sales ($m), 2006-12 59 Figure 28: Launch, core and expiry, sales ($m), 2006-12 60 Figure 29: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), King Pharmaceuticals 61 Figure 30: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), peer set 62 Figure 31: Externalization dependency, sales ($m), 2006-12 64 Figure 32: Growth drivers and resistors, externally vs. internallydiscovered products, sales ($m), 2006-12 65 Figure 33: Externalization dependency vs. peer set, % total sales,2006 66 Figure 34: Externalization dependency vs. peer set, % total sales,2012 67 Figure 35: Geographical sales breakdown ($m), 2006-12 68 Figure 36: Growth drivers and resistors by geography, sales ($m)2006-12 69 Figure 37: US dependency vs. peer set, % total sales, 2006 70 Figure 38: US dependency vs. peer set, % total sales, 2012 71 Figure 39: Molecule type sales breakdown ($m), 2006-12 73 Figure 40: Growth drivers/ resistors by molecule type, sales ($m),2006-12 74 Figure 41: Biologics dependency vs. peer set, % total sales, 200675 Figure 42: Biologics dependency vs. peer set, % total sales, 201276 Figure 43: IMS vs. company-reported ethical sales discrepancy

($m), 2006 99 Figure 44: IMS vs. company-reported ethical sales forecast growthrates (%), 2006-12 100 More market research reports? Go to http://www.reportlinker.comReportlinkerCopyright Business Wire 2007